Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Scan for outdated or missing drivers - takes under a minute3Repair Windows errors before they cause bigger problemsAssess the company’s development milestones, cash runway and executed debt terms together. A convertible note can create both a repayment obligation and future share dilution; whether it is paid in cash, converted into shares or settled another way depends on the contract. Start with the issuer’s latest filings and the actual note documents, not a headline debt figure or a runway estimate copied from another company.
Why do biotech development plans make cash runway hard to judge?
Biotechnology companies may need substantial funding for research, clinical trials, regulatory review and manufacturing before a product can generate revenue. Those steps take time and have uncertain outcomes. If a study is delayed or unsuccessful, or financing is unavailable, a company may need to change its development plans.
As an Amazon Associate I earn from qualifying purchases.
Map each material program to its current stage, next planned milestone, expected timing, trial design, manufacturing needs and regulatory steps. Then ask how much funding the company needs to reach each milestone—and what it would do if a trial slips, requires more work or fails. A trial stage or announced plan is not evidence that a treatment will be approved or become commercially successful.
Recommended Free Tools
Issuer filings illustrate the uncertainty without establishing a sector-wide rule. In its Form 10-Q for the quarter ended June 30, 2026, Latigo Biotherapeutics, Inc. said: “We may be unable to raise additional funds or to enter into such agreements or arrangements on favorable terms, or at all.” That is the company’s disclosure about its own circumstances, not a forecast for every biotech issuer.
#1 Best Overall
Reconstruct runway from current financial statements
Begin with the latest balance sheet and cash-flow statement. Separate unrestricted cash from restricted or otherwise unavailable balances. Account for operating cash use, accrued expenses, debt service, committed trial and manufacturing costs, and financing that has actually closed. Compare management’s stated runway with the assumptions behind it and the costs of upcoming milestones.
Build at least two scenarios: a base case using the company’s stated timeline and an adverse case in which a trial or financing is delayed. Treat a financing plan or expectation as prospective—not available cash—unless the transaction is binding and the funds are available.
What documents reveal the real debt obligation?
Read the latest debt footnote alongside the executed note or indenture, security agreement and every amendment. A filing summary may help locate key provisions, but the contract determines when payment or conversion is due and which party controls the choices.
- Proceeds and cost: Record face principal separately from cash proceeds after any original issue discount and fees. Note the coupon, any one-time interest charge, payment-in-kind terms, amortization schedule and maturity date.
- Conversion mechanics: Identify whether conversion is optional or automatic, its triggering events and dates, and the complete conversion-price formula. Check for discounts, valuation caps, floors, resets, lookback periods, default conversion prices and beneficial-ownership limits.
- Settlement: Determine whether principal and interest are paid or settled in cash, shares or a combination, and whether the issuer or holders choose the method. Check whether a corporate event can trigger cash settlement, redemption or repurchase.
- Creditor protections: Review collateral, lien priority, guarantees, covenants, events of default, cure periods, acceleration and cross-default provisions. These terms can affect financing, licensing, asset transactions and operating flexibility.
- Equity-linked rights: Include warrants and their exercise prices and adjustment provisions, as well as refinancing and change-of-control rights.
SEC filings show why the actual clauses matter: one issuer’s disclosure describes scheduled amortization, an original issue discount, a one-time interest charge and a conversion discount that may apply after default; another describes maturity cash payment and potential cash-settlement obligations. These are examples of terms to investigate, not assumptions about a different issuer. Brainstorm Cell Therapeutics’ Form 10-Q for the quarter ended June 30, 2026, for example, reports that issuer’s note amounts and terms; those disclosures are not representative market terms.
How much dilution could convertible notes cause?
Estimate shares using the contract’s conversion formula under several plausible future share or financing prices. A simple fixed-price illustration is principal and any converting interest divided by the conversion price, but that is not enough when the agreement includes a discount, cap, floor, reset or default formula. Apply the actual formula and its trigger conditions in each scenario.
- List each outstanding note, its principal, accrued interest and applicable conversion terms.
- For each scenario, determine which contractual price or formula applies, including any financing, market-price or default trigger.
- Calculate the shares that could be issued for each note, then add warrants, options and other potentially issuable securities.
- Compare ownership on the same fully diluted share-count basis before and after conversion. Show the assumptions and distinguish possible dilution from shares already issued.
Discounts or valuation caps can result in more shares for a noteholder than a simple calculation at the current share price would suggest. SEC-filed investor offering disclosures also call attention to the aggregate amount of notes issued and potentially to be issued. Assess all relevant instruments together rather than modeling only the most visible note.
Can the company repay its convertible debt at maturity?
Make a separate cash schedule for scheduled payments, amortization, maturity and any cash settlement that could follow a conversion or corporate event. Compare those obligations with cash expected to be available at the relevant dates—not just the current balance—and test whether the company can meet them if a planned financing does not close.
Conversion does not automatically eliminate repayment risk. Depending on the instrument, the issuer may owe cash at maturity, make scheduled payments before then, or owe cash in particular circumstances. Default remedies may allow acceleration, while liens and seniority can put creditors ahead of common shareholders with respect to the relevant assets or proceeds. The contract specifies which rights apply and who can exercise them.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How should you compare biotech companies or notes?
Use the same filing dates, assumptions and fully diluted share-count basis for each company. Keep business-development risk distinct from financing risk, then assess how they interact: a note due before the next value-defining milestone may create a different funding problem from one with a later maturity, even if the principal amounts appear similar.
Rank #4
| Compare | What to examine |
|---|---|
| Development and funding need | Stage and concentration of lead programs; timing and quality of next clinical or regulatory milestones; expected capital needs to reach them. |
| Cash runway | Unrestricted cash, operating cash use, committed costs, debt service and the assumptions behind management’s runway estimate. |
| Financing certainty | Funding already closed or binding and available versus prospective financing plans. |
| Debt economics | Cash proceeds versus face principal; interest and fees; amortization; maturity relative to runway; total repayment burden. |
| Conversion and dilution | Conversion formula, sensitivity to share or financing prices, possible cash settlement, and related warrants or other potential shares. |
| Control and priority | Collateral, lien priority, covenants, default and acceleration rights, and restrictions that could affect financing or business choices. |
What does reported interest expense tell you?
Reconcile reported interest expense with the note’s cash coupon, original issue discount, issuance costs and any conversion-related accounting described in the footnotes. Compare the contractual payment schedule with cash flows. Discounts and issuance costs may be amortized into reported interest expense, so reported expense and cash paid need not match in a period. Conversely, a modest reported interest amount does not remove principal repayment or dilution risk.
Accounting treatment depends on the instrument’s provisions and applicable standards; one issuer’s classification or expense treatment should not be generalized to every convertible note. Review the relevant footnote and cash-flow statement together.
What the available evidence can—and cannot—show
SEC issuer filings and an SEC-filed investor offering disclosure accessed October 4, 2026, provide company-specific terms and statements, not a representative average for biotech companies with convertible debt. No sector-wide average for prevalence, dilution or runway is established here. Issuer estimates and plans can change with new filings, trial events, amendments, financings and market prices, so use the target company’s latest disclosures and executed agreements.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
